Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638607 | 0.97 | AGTR1 (0.39) | AGTR1AGTR2MAPTLMNATLR7 | |
| SCHEMBL1206862 | 0.89 | AGTR1 (0.41) | AGTR1AGTR2MAPTLMNAHDAC1 | |
| SCHEMBL1637212 | 0.88 | MAPT (0.45) | AGTR1AGTR2MAPTTLR7HDAC1 | |
| SCHEMBL12894290 | 0.87 | MAPT (0.48) | AGTR1AGTR2MAPTLMNATLR7 | |
| SCHEMBL15509992 | 0.84 | TLR8 (0.46) | MAPTLMNATLR7HDAC1TLR8 | |
| SCHEMBL1638239 | 0.83 | AGTR1 (0.34) | AGTR1AGTR2MAPTTLR7TLR8 | |
| SCHEMBL1636416 | 0.81 | ACSS2 (0.40) | MAPTLMNATLR7HDAC1TLR8 | |
| SCHEMBL1205005 | 0.81 | TSHR (0.42) | AGTR1AGTR2 | |
| SCHEMBL15510198 | 0.80 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL1205003 | 0.80 | CXCR4 (0.53) | AGTR1AGTR2MAPTLMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20110046113-A1 | AMINE COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7833991-B2 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | AGTR1 1382/4885AGTR2 1282/4885MAPT 3333/4885 |
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | AGTR1 877/4885AGTR2 981/4885MAPT 3413/4885 |
| US-20110046113-A1 | AMINE COMPOUND AND USE THEREOF | NR0B2, NR1D2, NR0B1 | AGTR1 987/4885AGTR2 1058/4885MAPT 3600/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | AGTR1 1110/4885AGTR2 1171/4885MAPT 3184/4885 |
| US-20070208033-A1 | For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists | CXCR4, CXCR6, CCR5 | AGTR1 1253/4885AGTR2 1033/4885MAPT 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.